Members of The European Prevention of Alzheimer’s dementia (EPAD) initiative today announced the start of a novel collaboration between academic and private sectors to test innovative treatments for the prevention of Alzheimer’s dementia.
The goal of this initiative is the prevention of dementia in people with evidence of the condition (such as biomarker abnormalities as identified by specific tests), who have little or no complaints or clinical symptoms.
Alzheimer’s Society comment:
Dr Doug Brown, Director of Research and Development at Alzheimer’s Society said:
‘Large scale, collaborative projects like this are key to speeding up the search for new and better dementia treatments. By targeting large numbers of people in the preclinical stages of Alzheimer’s disease, this innovative approach hopes to find treatments that can delay or completely prevent the onset of dementia symptoms. Dementia research has been underfunded for such a long time. We fully support this bold commitment from the European Commission and all other partners involved.
‘There are 8.7 million people living with dementia in Europe so we need to do everything we can to make dementia research a priority. Alzheimer’s Society has pledged to spend at least £100m on dementia research in the next decade and we are calling for sustained action to tackle the global health challenge of dementia.’